

## Disclosure Statement

### Joint Working Project between;

- Mount Vernon Cancer Centre (MVCC) at East and North Hertfordshire NHS Trust and Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)

<b>Name of Project</b>	Immuno-Oncology Pathway at Mount Vernon
<b>Project Overview</b>	<p>The use of Immuno-oncology (I-O) therapies is continuing to grow within MVCC. Clinical indications and the number of eligible patients for I-O therapy are continuing to increase, the result of which will be a greater demand and pressure on hospital resources. Like for like, patients on I-O therapies can require more hospital appointments/admissions for treatment compared to conventional treatments. If nothing were to change, the centre would be unable to accommodate this demand and cancer waiting times and patient experience would be detrimentally affected. For this reason, the service has considered it prudent to initiate a project to review the total patient pathway for oncology elective treatments. The project aims to address:</p> <ul style="list-style-type: none"> <li>• To review the pathway from decision to treat to administration and to include toxicity management: <ul style="list-style-type: none"> <li>○ The growing number of tumour types where I-O therapies would be included as part of the clinical management;</li> <li>○ Rapidly escalating numbers of patients in who I-O therapies would be a treatment option in the future</li> <li>○ Consideration of key capacity elements such as SACT, out-patients, staff resources and accommodation</li> <li>○ A safe, sustainable, efficient and integrated service model for both now and the future</li> <li>○ Reduction in the wastage of oncology medicines</li> </ul> </li> </ul> <p>The cancer centre within Mount Vernon is well established however as treatments are changing it is rapidly outgrowing its accommodation. The main task for the centre is to maximise every resource, streamline processes to ensure the best patient care and further understand the accommodation and resource implication for the future are sustainable</p>
<b>Project Objectives</b>	<ul style="list-style-type: none"> <li>• To maximise and reduce wastage of resources in the pathway of anti-cancer treatment and subsequent reviews/treatments, both in the short term and a longer time frame (2021)</li> <li>• To maintain or reduce the time between decision to treat and administration of anti-cancer treatment and subsequent reviews/treatment</li> <li>• Ensure that patient anxiety is minimised through controllable elements within the patient journey and that this then leads to greater patient satisfaction</li> <li>• Better understand the demand on accommodation and resources for the longer term with the impact on I-O therapies</li> </ul>
<b>Patient Benefits</b>	<ul style="list-style-type: none"> <li>• Improved patient experience and reducing potential anxiety that may be felt by some patients about the duration of time from decision to treat (DTT) to treatment administration</li> <li>• A service that meets the patient/service user requirements and needs and is consistent with person-centred values (for example: choice, control, independence, empowerment)</li> <li>• Improved patient experience through provision of a streamlined, efficient and patient focused service</li> </ul>
<b>Stakeholders</b>	Mount Vernon Cancer Centre (MVCC) Bristol-Myers Squibb (BMS)
<b>Timelines</b>	The Project will start from the date on which the disclosure statement goes live on the BMS website and will finish 12 months after this date

Produced by **Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)** with **Mount Vernon Cancer Centre (MVCC)**

ONCUK1900114-03  
Date of Preparation: January 2019